HC Wainwright Issues Pessimistic Outlook for ENLV Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Equities research analysts at HC Wainwright reduced their Q1 2026 earnings estimates for Enlivex Therapeutics in a research note issued to investors on Tuesday, April 7th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.02) per share for the quarter, down from their prior forecast of ($0.01). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.70) per share. HC Wainwright also issued estimates for Enlivex Therapeutics’ Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.08) EPS.

A number of other analysts also recently commented on ENLV. Wall Street Zen downgraded shares of Enlivex Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Enlivex Therapeutics currently has a consensus rating of “Hold” and an average target price of $16.50.

Enlivex Therapeutics Stock Up 12.0%

Shares of Enlivex Therapeutics stock opened at $0.93 on Thursday. Enlivex Therapeutics has a 52-week low of $0.66 and a 52-week high of $2.10. The company’s 50-day simple moving average is $1.08 and its 200-day simple moving average is $1.02. The firm has a market cap of $221.50 million, a price-to-earnings ratio of -1.70 and a beta of 1.68.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ENLV. Virtu Financial LLC acquired a new position in Enlivex Therapeutics in the 4th quarter valued at about $33,000. Invesco Ltd. purchased a new position in shares of Enlivex Therapeutics during the fourth quarter valued at approximately $43,000. XTX Topco Ltd lifted its stake in shares of Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock valued at $43,000 after buying an additional 19,132 shares during the period. Jane Street Group LLC lifted its stake in shares of Enlivex Therapeutics by 244.1% during the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after buying an additional 52,553 shares during the period. Finally, Susquehanna International Group LLP purchased a new position in shares of Enlivex Therapeutics during the third quarter valued at approximately $57,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

Trending Headlines about Enlivex Therapeutics

Here are the key news stories impacting Enlivex Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target on ENLV to $20 and maintained a Buy rating — a very bullish signal that highlights the firm’s long-term confidence and may attract momentum/coverage-driven buying. Benzinga Price Target Raise
• Positive Sentiment: Ondo Finance launched ENLVon, a tokenized representation of Enlivex ordinary shares on its Global Markets platform — this can increase liquidity, fractional ownership, and access to new investor pools, which is typically viewed positively for otherwise thinly traded small-cap stocks. Ondo Tokenization (GlobeNewswire) Ondo Tokenization (Business Insider)
• Neutral Sentiment: HC Wainwright published quarterly and FY2027 EPS projections (mostly negative EPS of ~$0.02 per quarter and FY -$0.09) alongside its $20 target — useful for modeling but consistent with a developmental-stage biotech that is not yet profitable. HC Wainwright Estimates (MarketBeat)

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.